CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on validating a phospholipid biomarker to predict chemotherapy response in breast cancer patients using advanced MRI technology. It aims to improve detection accuracy and expedite FDA approval through a comparative study using different MRI systems.
Metabolic Imaging with RF Antennas to predict Chemotherapy Efficacy:
We will validate the phospholipid biomarker that can predict response of chemotherapy in patients with breast cancer using the most powerful MRI system in the world.
In particular the ratio of phosphoethanolamine (PE) to glycerophosphocholine (GPC), metabolites from the build up and breakdown of cell membranes, have been shown to increase accuracy in prediction of chemotherapy response from 75% to 96% [1].
At the clinically ava…
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United States, Minneapolis Mn
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, UTRECHT
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
